Stock LIPO LIPELLA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Lipella Pharmaceuticals Inc.

Equities

LIPO

US53630L1008

Delayed Nasdaq
Other stock markets
 12:28:46 2024-04-30 pm EDT 		5-day change 1st Jan Change
0.7218 USD -0.45% Intraday chart for Lipella Pharmaceuticals Inc. +0.80% -29.24%
Apr. 17 Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board CI
Apr. 09 Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
AQ
Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board
CI
Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target
MT
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
AQ
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
AQ
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
AQ
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
AQ
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
CI
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
AQ
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
AQ
Wall Street Set to Open Lower Friday; Employment Growth Tops Forecasts
MT
Top Premarket Decliners
MT
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Lipella Gets FDA Orphan Designation for LP-310 in Oral Graft-vs-Host Disease
DJ
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease
PR
Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
PR
Lipella Pharmaceuticals Inc. announced that it has received $1.998685 million in funding
CI
Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
PR
Lipella Pharmaceuticals Inc. announced that it expects to receive $1.998685 million in funding
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LIPO Stock
  4. News Lipella Pharmaceuticals Inc.